Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lexicon Pharmaceuticals reports strong Q4 performance and eyes growth

Lexicon Pharmaceuticals showcased promising drug candidates and financial stability in Q4 2022.
While facing challenges in revenue generation and expense management, the company is strategically positioned for growth.
Opportunities lie in commercial launches, Phase 3 advancements, and potential partnerships to drive future success.
Overall, Lexicon's focus on maximizing asset value and advancing key drugs positions them for long-term success in the pharmaceutical market.

Lexicon Pharmaceuticals reports robust Q1 performance and eyes market expansion

Lexicon Pharmaceuticals showcased strong financials, promising drug candidates, and strategic confidence in market success.
Challenges lie in market penetration strategies, FDA feedback, and successful commercialization amidst competition.
Opportunities abound with upcoming sotagliflozin launch, advancing LX9211, and leveraging unique data for growth.

Lexicon Pharmaceuticals reports strong Q2 earnings and advances key treatments

Lexicon Pharmaceuticals demonstrated financial stability and strategic progress in Q2 2023, supported by strong cash reserves and key regulatory milestones.
The company's focus on patient-centric initiatives and upcoming product launches positions it for sustained growth and market success.
Challenges in market penetration and revenue realization require targeted strategies, while opportunities in market expansion and pipeline development offer avenues for growth.
Overall, Lexicon Pharmaceuticals shows promise with a solid foundation for future success, driven by innovation and market-focused strategies.

Lexicon Pharmaceuticals reports Q3 loss, highlights INPEFA progress and global expansion

Lexicon Pharmaceuticals faces challenges in market access and inventory trends while capitalizing on opportunities through geographic expansion and potential partnerships. The company's financial performance in Q3 2023 showed increased expenses but progress in prescription demand for INPEFA.

Lexicon Pharmaceuticals reports strong Q1 performance and growth opportunities

Lexicon Pharmaceuticals showcased strong performance and progress in Q1 2024, with a focus on product launches and market access.
Despite challenges in achieving full access and addressing specific patient needs, the company remains optimistic about future growth opportunities.
Positive customer feedback, ongoing pipeline advancements, and strategic market considerations position Lexicon well for future success and sales acceleration.

Lexicon Pharmaceuticals reports Q3 progress amidst financial challenges and opportunities

Lexicon Pharmaceuticals showcased progress in key development programs and strategic partnerships in Q3 2024.
Despite financial challenges, the company's operational strengths and focus on growth opportunities are notable.
Navigating uncertainties around ZYNQUISTA and competition in the market are key challenges ahead.
Overall, the company's performance, strengths, challenges, and opportunities shape its strategic outlook for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The FDA accepts Lexicon's (LXRX) resubmission seeking approval for sotagliflozin to treat adults with type 1 diabetes. A final decision is expected by Dec 20.

FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug

THE WOODLANDS, Texas, July 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced that the Lexicon Board of Directors has appointed Mike Exton, Ph.D. as chief executive officer and director of Lexicon.

Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director

Arcutis Biotherapeutics

Bicycle Therapeutics Plc - ADR

Castle Biosciences Inc

Prime Medicine Inc

We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX.

Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio

Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease

Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes

Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP)

Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

THE WOODLANDS, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 84th Scientific Sessions of the American Diabetes Association being held June 21 - 24, 2024 at the Orange County Convention Center in Orlando, Florida.

Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association

NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, announced today that it has been selected by Lexicon Pharmaceuticals, Inc. to help advance PROGRESS, a Phase 2b study of LX9211 in diabetic peripheral neuropathic pain (DPNP), with the potential for LX9211 to become the first new, non-opioid drug approved for neuropathic pain in over two decades. Medidata will enable Lexicon to accelerate patient enrollm.

Lexicon Pharmaceuticals Selects Medidata to Help Advance First Non-Opioid Drug for Neuropathic Pain in Over Two Decades

THE WOODLANDS, Texas, May 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies Global Healthcare Conference. Jeff Wade, Lexicon's president and chief financial officer and Craig Granowitz, M.D., Ph.D., Lexicon's senior vice president and chief medical officer, will participate in a moderated discussion on Wednesday, June 5, 2024, at 3:00 pm ET.

Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024

Analysis adds to the body of evidence differentiating INPEFA as a dual oral inhibitor of SGLT2 and SGLT1 Analysis adds to the body of evidence differentiating INPEFA as a dual oral inhibitor of SGLT2 and SGLT1

New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction

THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Bank of America Securities Healthcare Conference 2024. Jeff Wade, Lexicon's president and chief financial officer, will make a company presentation on Tuesday, May 14, 2024, at 8:00 am PDT (11:00 am ET).

Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q1 2024 Earnings Conference Call May 2, 2024 5:00 PM ET Company Participants Lisa DeFrancesco - Head of Investor Relations and Strategy Lonnel Coats - Chief Executive Officer and Director Jeffrey Wade - President and Chief Financial Officer Craig Granowitz - Senior Vice President and Chief Medical Officer Tom Garner - Senior Vice President and Chief Commercial Officer Alan Main - Executive Vice President of Innovation & Chemical Sciences Conference Call Participants John Geelan - Piper Sandler Roanna Ruiz - Leerink Partners Andrew Tsai - Jefferies Joseph Stringer - Needham & Company Operator Good day, everyone, and welcome to the Lexicon Pharmaceuticals First Quarter 2024 Financial Results Conference Call. At this time all participants are in a listen-only mode.

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2024 Earnings Call Transcript

Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.17 per share a year ago.

Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates

Commercial launch of INPEFA ® (sotagliflozin) for Heart Failure continues to progress

Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced that Lonnel Coats has provided notice of his retirement as chief executive officer and as a member of its board of directors, in each case effective July 7, 2024, his 10th anniversary with the company. The board of directors has initiated a search for a new chief executive officer which will consider both internal and external candidates.

Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals

Includes Business and Scientific Updates from Lexicon Executives and Leading Medical Experts in Hypertrophic Cardiomyopathy, Type 1 Diabetes and Diabetic Peripheral Neuropathic Pain Includes Business and Scientific Updates from Lexicon Executives and Leading Medical Experts in Hypertrophic Cardiomyopathy, Type 1 Diabetes and Diabetic Peripheral Neuropathic Pain

Lexicon Pharmaceuticals to Host 2024 Investor Day

Lexicon (LXRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy

THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two sodium glucose transport proteins (SGLT2 and SGLT1), will be delivered during the American College of Cardiology 73rd Annual Scientific Session & Expo being held April 6 - 8, 2024 in Atlanta, Georgia, including results from a post-hoc evaluation of the efficacy of sotagliflozin in reducing stroke events in patients with type 2 diabetes, chronic kidney disease (CKD), and high cardiovascular (CV) risk in the SCORED Phase 3 clinical trial.

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

New post hoc analysis of data from Lexicon's (LXRX) phase III study shows improvements in glycemic control when treated with sotagliflozin for type 1 diabetes and chronic kidney disease.

Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin

Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.16 per share a year ago.

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates

Commercial launch of INPEFA ® (sotagliflozin) continues to progress. with increasing demand across the cardiology community and improving payer access

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced it has entered into a securities purchase agreement (the “purchase agreement”) for a private investment in public equity financing that is expected to result in gross proceeds of approximately $250 million, before deducting placement agent fees and offering expenses. Pursuant to the terms of the purchase agreement, Lexicon will sell approximately 2.3 million shares of series a convertible preferred stock (the “Series A Convertible Preferred Stock”), at a price per share of $108.50, convertible into approximately 115.2 million shares of its common stock, par value $0.001, to a select group of accredited investors pursuant to the terms of the purchase agreement.

Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for

Novavax

Plug Power

Pockets of optimism can always be found among Wall Street analysts. Three off-the-radar stocks could deliver jaw-dropping gains in 2024, based on the high-water price targets of three analysts.

3 Under-the-Radar Stocks With 340% to 762% Upside in 2024, According to Select Wall Street Analysts

Lexicon Pharmaceuticals has made progress in getting its lead drug Inpefa onto formularies and securing reimbursement agreements with insurers. Multiple studies support the cost efficacy of Inpefa for heart failure, and this could become a more significant competitive differentiator for insurers if real-world experience follows accordingly. Lexicon also has other opportunities in its pipeline, including the development of LX9211 for diabetic peripheral neuropathic pain and a possible path to approval for sotagliflozin for Type 1 diabetes.

Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do

Lucid Group

Nikola

Wall Street enjoyed a phenomenal 2023, with growth stocks leading the broader market higher. Consensus estimates suggest three fast-paced stocks will see their sales skyrocket by 112% to 1,106% in 2024.

News for Lexicon Pharmaceuticals Stock (LXRX)